Reviewed by Michael Gill, B. Sc.
25 Lou Gehrigs Disease Clinical Trials Near Me
Top Hospitals for Lou Gehrigs Disease Clinical Trials
Image of Massachusetts General Hospital in Massachusetts.
Massachusetts General Hospital
Boston
12Active Trials
60All Time Trials for Lou Gehrigs Disease
2001First Lou Gehrigs Disease Trial
Image of Hospital for Special Surgery in New York.
Hospital for Special Surgery
New York
6Active Trials
17All Time Trials for Lou Gehrigs Disease
2012First Lou Gehrigs Disease Trial
Top Cities for Lou Gehrigs Disease Clinical Trials
Most Recent Lou Gehrigs Disease Clinical Trials
Top Treatments for Lou Gehrigs Disease Clinical Trials
Treatment Name
Active Lou Gehrigs Disease Clinical Trials
All Time Trials for Lou Gehrigs Disease
First Recorded Lou Gehrigs Disease Trial
Reldesemtiv
2
3
2017
AMX0035
2
5
2017
Pridopidine
2
2
2020
Mobile neural decoding platform (mobile iBCI)
1
1
2023
PTC857
1
1
2022
Recently Completed Studies with FDA Approved Treatments for Lou Gehrigs Disease
Treatment
Year
Sponsor
Theracurmin HP
2020
Richard Bedlack, M.D., Ph.D.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 27th, 2021

Last Reviewed: October 14th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Rosenbek JC, Robbins JA, Roecker EB, Coyle JL, Wood JL. A penetration-aspiration scale. Dysphagia. 1996 Spring;11(2):93-8. https://pubmed.ncbi.nlm.nih.gov/87210662 Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9. Review. https://pubmed.ncbi.nlm.nih.gov/114648473 Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999 Oct 31;169(1-2):13-21. https://pubmed.ncbi.nlm.nih.gov/105400024 Crary MA, Mann GD, Groher ME. Initial psychometric assessment of a functional oral intake scale for dysphagia in stroke patients. Arch Phys Med Rehabil. 2005 Aug;86(8):1516-20. https://pubmed.ncbi.nlm.nih.gov/160848015 Latham BD, Oskin DS, Crouch RD, Vergne MJ, Jackson KD. Cytochromes P450 2C8 and 3A Catalyze the Metabolic Activation of the Tyrosine Kinase Inhibitor Masitinib. Chem Res Toxicol. 2022 Sep 19;35(9):1467-1481. doi: 10.1021/acs.chemrestox.2c00057. Epub 2022 Sep 1. https://pubmed.ncbi.nlm.nih.gov/360488776 Glass JD, Boulis NM, Johe K, Rutkove SB, Federici T, Polak M, Kelly C, Feldman EL. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells. 2012 Jun;30(6):1144-51. doi: 10.1002/stem.1079. https://pubmed.ncbi.nlm.nih.gov/224159427 Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, Hamada C, Kondo K, Yoneoka T, Akimoto M, Yoshino H; Edaravone ALS Study Group. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):610-7. doi: 10.3109/21678421.2014.959024. Epub 2014 Oct 6. https://pubmed.ncbi.nlm.nih.gov/252860158 Weiss JN, Levy S. Neurologic Stem Cell Treatment Study (NEST) using bone marrow derived stem cells for the treatment of neurological disorders and injuries: study protocol for a nonrandomized efficacy trial. Clin Trials Degener Dis. 2016 [cited 2019 Jun 18];1:176-80. 9 Boulis NM, Federici T, Glass JD, Lunn JS, Sakowski SA, Feldman EL. Translational stem cell therapy for amyotrophic lateral sclerosis. Nat Rev Neurol. 2011 Dec 13;8(3):172-6. doi: 10.1038/nrneurol.2011.191. Review. https://pubmed.ncbi.nlm.nih.gov/2215851810 Cella D, Nowinski C, Peterman A, Victorson D, Miller D, Lai JS, Moy C. The neurology quality-of-life measurement initiative. Arch Phys Med Rehabil. 2011 Oct;92(10 Suppl):S28-36. doi: 10.1016/j.apmr.2011.01.025. https://pubmed.ncbi.nlm.nih.gov/21958920